TTM
−$60.08M
YoY change
-17.2%
5Y CAGR
—
Peak year (2019)
−$7.45M
Cumulative operating income
−$314.57M
Operating Income history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: −$67.88M
Operating Income growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: -17.2%
Operating Income history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | −$67.88M | -17.2% | +$14.14M | ||
| 2024 | −$82.02M | +103.6% | −$41.74M | ||
| 2023 | −$40.27M | -10.8% | +$4.86M | ||
| 2022 | −$45.13M | +26.5% | −$9.46M | ||
| 2021 | −$35.67M | +70.5% | −$14.75M | ||
| 2020 | −$20.93M | +181.0% | −$13.48M | ||
| 2019 | −$7.45M | — | — |
- 2025−$67.88M-17.2%
- 2024−$82.02M+103.6%
- 2023−$40.27M-10.8%
- 2022−$45.13M+26.5%
- 2021−$35.67M+70.5%
- 2020−$20.93M+181.0%
- 2019−$7.45M—
Operating Income values are taken from Climb Bio's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Climb Bio (CLYM)
According to Climb Bio's latest reported financial statements, the company's current operating income (TTM) is −$60.08M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual operating income for Climb Bio (CLYM) came in at −$67.88M – declined 17.2% year-over-year.
The highest annual operating income of −$7.45M was reported in 2019. The lowest in the available history was −$82.02M in 2024.
Climb Bio Operating Income by Year
Climb Bio Operating Income 2025: −$67.88M
2025's operating income for Climb Bio came in at −$67.88M, declined 17.2% below 2024.
Climb Bio Operating Income 2024: −$82.02M
Climb Bio posted operating income of −$82.02M in 2024, surged 103.6% from 2023. This figure represents the lowest annual value in the available history.
Climb Bio Operating Income 2023: −$40.27M
In 2023, Climb Bio reported operating income of −$40.27M, declined 10.8% below 2022.
Climb Bio Operating Income 2022: −$45.13M
Climb Bio operating income in 2022 was −$45.13M, grew 26.5% from 2021.
Climb Bio Operating Income 2021: −$35.67M
Climb Bio operating income in 2021 was −$35.67M.
See more financial history for Climb Bio (CLYM).
Sector peers by Operating Income
Healthcare peers of Climb Bio (CLYM), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation